NCT00706849 - Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

May 31, 2010

Conditions

Heterozygous Familial HypercholesterolemiaCoronary Artery Disease

Interventions

DRUG

mipomersen sodium

200 mg /mL

DRUG

placebo

1 mL matching placebo

Trial Locations (48)

10032

New York

10065

The Rogosin Institute Comprehensive Lipid Control Center, New York

27710

Durham

28204

Charlotte

28211

Charlotte

32514

Pensacola

32901

Melbourne

37232

Nashville

44223

ResEvo, LLC, Cuyahoga Falls

45005

Franklin

45212

Cincinnati

60540

Naperville

60610

Chicago

63110

St Louis

66160

Kansas City

73120

Oklahoma City

75220

Dallas

75226

Dallas

76051

Grapevine

77093

Houston

78229

San Antonio

84108

Salt Lake City

89144

Las Vegas

90048

Los Angeles

91360

Thousand Oaks

92093

La Jolla

92260

Newport Beach

92691

Mission Viejo

92705

Santa Ana

97239

Portland

98104

Seattle

06606

Bridgeport

04005

Biddeford

04074

Scarborough

02114

Boston

48109-5853

Ann Arbor

03301

Concord

T2E 7C5

Calgary

V6Z 1Y6

Vancouver

R3A 1R9

Winnipeg

N6A 5K8

London

M5C 2T2

Toronto

M5G 2C4

Toronto

G7H 5H6

Chicoutimi

H1T 1C8

Montreal

H2W 1R7

Montreal

G1V 4M6

Saint Foy

J1H 5N4

Sherbrooke